Physician

Kailash R Kedia, M.D.

According to 2025 Medicare claims, Kailash Kedia, M.D. (NPI: 1548240286) practices urology in the Cleveland, OH market, with the plurality of this provider's patient population coming from Cuyahoga, OH. This provider's primary affiliated billing organization is CLEVELAND UROLOGY ASSOCIATES, INC (NPI: 1265509053; TIN: 34-1316840) and primary practice location at 44130-3348. Kedia is affiliated with the Cleveland Clinic Medicare ACO, LLC (ACO ID: A2729), participating under the MSSP model.

Kedia's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 925 traditional Medicare patients, billed 13,551 HCPCS/CPT codes, and received $619,015 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 5,168 prescription claims across 1,068 beneficiaries totaling $2,152,081 in drug costs, led by Xtandi (Enzalutamide). DME data shows 54 claims. Open Payments data shows 81 records totaling $4,119. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a higher plateau to a lower plateau, from $787,540 to $619,015. In contrast, Part D prescription costs have moved sharply higher in recent years, from $523,586 to $2,152,081. For DME billing, this smaller-volume category fell sharply in recent years, from $207 to $173.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,867	17,335	$787,540
2016	2,003	19,150	$981,472
2017	1,696	13,977	$631,188
2018	1,576	13,505	$801,477
2019	1,443	17,656	$736,674
2020	1,252	11,961	$468,617
2021	1,184	11,876	$447,649
2022	1,086	12,082	$404,574
2023	960	10,410	$435,929
2024	925	13,551	$619,015

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	1,140	5,685	$523,586
2016	1,153	5,781	$548,342
2017	1,171	5,661	$476,531
2018	1,189	5,370	$561,627
2019	1,140	5,213	$660,007
2020	1,069	5,040	$769,193
2021	1,078	5,296	$1,084,565
2022	1,040	4,957	$1,240,036
2023	1,023	5,019	$1,585,471
2024	1,068	5,168	$2,152,081

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	194	$21,303
2016	12	251	$32,496
2017	N/R	192	$36,988
2018	12	153	$30,873
2019	12	119	$25,302
2020	N/R	94	$26,487
2021	N/R	44	$15,984
2022	N/R	66	$16,323
2023	N/R	83	$19,336
2024	N/R	54	$17,901

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	432	841	$87
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	302	426	$61
84153	Psa (prostate specific antigen) measurement, total	369	754	$18
36415	Insertion of needle into vein for collection of blood sample	523	1,066	$9
81000	Manual urinalysis test with examination using microscope, non-automated	618	1,454	$4

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	123	3,690	$1,739,416
Orgovyx	Relugolix	56	1,680	$149,918
Myrbetriq	Mirabegron	109	6,210	$94,193
Gemtesa	Vibegron	31	2,370	$39,083
Finasteride	Finasteride	1,379	119,198	$17,980

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4351	Intermittent urinary catheter; straight tip, with or without coating (teflon, silicone, silicone elastomer, or hydrophilic, etc.), each	N	N/R	39	$17,513
A4357	Bedside drainage bag, day or night, with or without anti-reflux device, with or without tube, each	N	N/R	15	$388

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	81	$4,119	Dendreon Pharmaceuticals LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Kailash R. Kedia, M.D.?

Tedicare shows public-source Medicare data for Kailash R. Kedia, M.D. (NPI 1548240286), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Kailash R. Kedia, M.D. have ACO affiliation data?

Kailash R. Kedia, M.D. is shown with ACO affiliation data for Cleveland Clinic Medicare ACO, LLC (MSSP, ACO ID A2729).

What billing organization is linked to Kailash R. Kedia, M.D.?

Kailash R. Kedia, M.D. is linked to CLEVELAND UROLOGY ASSOCIATES, INC (billing NPI 1265509053) in the available physician profile data.

Does Kailash R. Kedia, M.D. have Open Payments data?

Kailash R. Kedia, M.D. has 81 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.